Medios AG (ILM1) Fair Value & Analysis
Healthcare · DE · Market cap €347M
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from €24.83 to €17.07 (−31.3%) since Jun 23, 2026. Share price −11.2% over the past month.
Price vs Fair Value (12 months)
12‑month range €11.74 – €17.32 · fair‑value band €13.31 – €23.45 · the €12.08 price screens below the €17.07 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Medios AG (ILM1) currently trades at €12.08, while our model-based Fair Value estimate is €17.07 — implying the stock looks roughly 41.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Medios AG generated revenue of €2.1B at a net margin of 0.7%. Revenue grew 8.9% year over year. It earns a return on equity of 2.7%. Net debt stands at €107M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medios AG reported revenue of €2.1B in FY2025 versus €1.4B in FY2021, a compound +11.2%/yr. Reported net income was €15.4M in FY2025, compounding +20.0%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$999.49 | R$1,236 | +24% |
| Cencora, Inc C1CO34 | R$707.04 | R$79.88 | -89% |
| Cardinal Health, Inc CAH | $201.74 | $92.07 | -54% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Sitka Gold Corp SIG | A$2.92 | A$1.20 | -59% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medios AG (ILM1) undervalued?
What is the fair value of ILM1?
What is the quality score of ILM1?
What is the revenue of Medios AG (ILM1)?
What is the net profit margin of ILM1?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.